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Abstract
Urological applications of neuromodulation and neurostimulation are among 
the most evolving fields for these technologies. First approved for management 
of refractory urge incontinence, different modalities of neuromodulation and 
stimulation have been tested, applied and verified for a vast spectrum of voiding 
and pelvic floor dysfunction disorders. The modalities of delivering this treatment 
have also evolved in the last three decades, with a focus on sacral neuromodulation. 
The experimental and established “off-label” applications of neuromodulation have 
also encompassed chronic pelvic pain disorders, including chronic prostatitis and 
bladder pain syndrome, among others. In this chapter, we discuss all the hypoth-
esized theories suggested on how this technology provides therapeutic potential for 
a number of chronic and debilitating urological conditions, the modes of delivery 
be it anterior, sacral, and posterior tibial to name a few, and the evolving and future 
applications.
Keywords: neuromodulation, sacral neuromodulation, posterior tibial nerve 
stimulation, lower urinary tract dysfunction
1. Introduction
Neuromodulation in urological practice is not a novel concept, but certainly one 
that has lagged in dissemination. The first reports of the use of neuromodulation to 
stimulate bladder emptying date back to as early as the 1970s, although the results 
back then were disappointing [1]. It was not until 1988 that Schmidt and Tanagho 
restarted the discussion on applications of neuromodulation and electrical stimula-
tion of the sacral nerve in urology, and since then reports on different novel tech-
niques and applications ensued [2, 3]. The term “neurostimulation” was recoined 
later to “neuromodulation,” as experts in the neuro-urology field argued that 
electrical currents do not only stimulate but rather modulate the messages carried by 
different nerves involved in the micturition reflex and the lower urinary tract [4].
1.1  Review of lower urinary tract innervation and processes of storage and 
micturition
The urinary bladder has both afferent and efferent innervation. Efferent inner-
vation is both sympathetic and parasympathetic. The hypogastric nerve carries 
postganglionic sympathetic fibers innervated at the inferior mesenteric ganglion 
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by preganglionic fibers arising from T11-L2. Their main function is inhibition of 
bladder wall contraction and excitation of the internal urethral sphincter, both 
necessary to maintain continence and facilitate urinary storage. Parasympathetic 
efferents which originate preganglionically from the sacral spinal cord through 
the S2 to S4 spinal nerve roots reach postganglionic fibers in the pelvic plexus and 
bladder wall and through stimulation of release of acetylcholine act on muscarinic 
receptors to produce bladder wall contraction.
Afferent innervation from the bladder consists of small myelinated Aδ fibers, 
which relay information via the pelvic and pudendal nerves to the sacral spinal cord 
at S2 to S4 about the properties of a bladder contraction, and synapse with spinal 
interneurons and autonomic fibers constituting what is known as the micturition 
reflex arc. The interneurons also relay information to higher centers, namely the 
periaqueductal gray and pontine micturition centers, as well as the hypothalamus, 
thalamus, prefrontal cortex and angulate gyrus in the cerebrum, among other 
areas. These centers have a modulatory voluntary control over bladder function 
and what is perceived by us from somatic sensation in the bladder and pelvic floor, 
such as sensation of bladder fullness. Bladder afferents also consist of unmyelinated 
C-fibers which are inactive in normal circumstances but are responsible for trans-
mission of noxious stimuli such as bladder pain and are involved in the development 
of neurologic lower urinary tract dysfunction [1].
During the phase of urinary storage, information about increasing bladder 
volume and pressure is carried by afferent discharges that stimulate both the 
sympathetic and parasympathetic preganglionic fibers. While the stimulated 
parasympathetic fibers would elicit a bladder contraction, their activity is inhib-
ited by sympathetic discharges at the postganglionic level, which also maintain 
contraction of the internal urethral sphincter at the level of the bladder neck and 
contraction of the pelvic floor in response to bladder filling. This coordination of 
afferent and efferent pathways ensures stable bladder filling and urinary storage 
and subsequently continence. Beyond a certain threshold of bladder filling, afferent 
discharges trigger the micturition reflex at the pontine level. This reflex results in 
inhibition of sympathetic and efferent continence signals and allowance of para-
sympathetic mediated bladder contractions to facilitate bladder emptying, preceded 
by relaxation of the urinary sphincters and pelvic floor.
Any interruption at the gross or microcellular level of these neural circuits 
would result in voiding dysfunction, be it by increased bladder sensation resulting 
in urinary frequency as is the case in overactive bladder and urgency-frequency 
disorders, loss of continence as in urgency urinary incontinence, loss of bladder 
sensation or inability to generate a voiding pressure as in non-obstructive urinary 
retention, or formation or upregulation of pathological neural circuits for reflex 
bladder activity or transmission of noxious stimuli such as is neurogenic bladder or 
pelvic pain disorders.
1.2 Mechanisms of action of neuromodulation of lower urinary tract
Neuromodulation of the lower urinary tract aims to restore lost or dysfunctional 
neural functions to fulfill the two main functions of the bladder, storage and voiding. 
Artificial stimulators directly or indirectly apply electrical stimulation that achieves 
this purpose. Through continuous or intermittent electrical stimuli at different 
nerves and sites, neuromodulation treats both bladder over- and under-activity, as 
well as pelvic and bladder pain [5].
The modes by which these electrical stimulations achieve such restoration differ 
from one type of neuromodulation to the other, and this will be further discussed in 
each section.
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1.3 General indications
Neuromodulation in urology is aimed at control of uninhibited bladder contrac-
tions to eliminate sensation of urgency and provide appropriate urinary continence. 
This is the scenario for overactive bladder disease and neurogenic bladder overactiv-
ity. Inability to void resulting in urinary retention is also corrected by neuromodula-
tion, though the literature has been less evident for neurogenic causes of retention 
versus the established restorative effects on voiding in idiopathic non-obstructive 
urinary retention (NOUR). Other effects through action on shared nerves between 
the lower urinary tract and the pelvic floor musculature are less reported on and are 
yet to be approved, but results have shown consistent alleviation of pelvic pain and 
sexual dysfunction parameters.
2. Neuromodulation modalities in urology
The spectrum of neuromodulation modalities in urology has evolved yet focuses 
around two manners that correspond to our understanding of the innervation of the 
lower urinary tract and pelvic floor muscles: sacral neuromodulation, by sacral ante-
rior root stimulation, sacral nerve modulation and recently pudendal nerve stimula-
tion (PNS) and its derivatives, and less invasive neuromodulators and peripheral 
nerve stimulators, the most studied of which is posterior tibial nerve stimulation.
2.1 Sacral anterior root stimulation
Though this mode of urological neuromodulation is almost of historical interest 
in the face of current advances in the field and the dominance of sacral neuromodu-
lation, it yet deserves honorable mention as it paved the way to utilize the sacral 
region for restoration of bladder function. Through stimulation of the anterior 
sacral nerve, both bladder parasympathetic efferents and somatic motor fibers 
to the external urethral sphincter are activated. This ventral activation facilitates 
intermittent bladder emptying [1].
Brindley in 1976 implanted intradurally and bilaterally on the ventral roots from 
S2 to S5 subcutaneous cables that were externally powered and would provide on-
demand electromagnetic stimulation to facilitate voiding [5–7]. He later modified 
his procedure by performing posterior rhizotomy at the S2–S3 level during implan-
tation of the stimulator to improve the continence outcome by eliminating the effect 
C-fiber bladder afferents had on amplifying the micturition reflex. This is what was 
later named the Brindley procedure, and its popularity phased out years later as 
more studies and reports demonstrated debilitating and unacceptable complications 
such as sacral dermatome hyperalgesia, cerebrospinal fluid leak, and damage to the 
anterior nerve root. The procedure, however, remains indicated for patients with 
complete spinal cord injury (SCI) with maintained bladder reflexes [1, 7–9].
2.2 Sacral neuromodulation
The first reports describing the application of sacral neuromodulation were 
by Schmidt and Tanagho, the latter concentrating on its application in neurogenic 
lower urinary tract dysfunction [2, 3]. Since then, both experimental and approved 
applications and research aiming to understand the mechanism of action by which 
sacral neurostimulation, or more appropriately now termed sacral neuromodulation 
(SNM), affects and rehabilitates the functions of the lower urinary tract, both in 
facilitating bladder storage and voiding, has expanded. Researchers also embarked 
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on assessing its efficacy, particularly cost-effectiveness, when compared to other 
modes of treatment for its indications. SNM is, perhaps, the best studied mode of 
neuromodulation in urology [5].
Compared to the Brindley procedure, SNM posed numerous advantages and 
technical differences. The SNM procedure involves extradural electrode implanta-
tion usually in one of the paired S3 foramens. It does not require posterior rhizotomy 
either. This minimized the risks of nerve root injury or cerebrospinal fluid leakage. 
It provides continuous electrical stimulation to the nerves in its proximity and 
is controlled remotely without the need for subcutaneous cables as it has a built 
in-battery and antenna. It also modulates for restoration of normal micturition and 
suppresses bladder overactivity, which made it applicable to non-neurogenic voiding 
dysfunctions as well [1, 3].
The first SNM device made commercially available was the Interstim® (Medtronic 
Neuromodulation, Minneapolis USA). It was first approved in 1997 by the US Food & 
Drug Administration (FDA) for use in refractory urge incontinence, and later in 1999 
its approval was expanded to include significant urgency, frequency, and idiopathic 
urinary retention. The US market was the most enthusiastic to adopt it, and back then 
and by the year 2004 15,000 units were implanted, the majority of which were in the 
USA [10, 11]. Since then, the rates of SNM implantations increased by at least 10 to 
20-folds [12, 13].
Sacral neuromodulation is dedicated to the S3 foramen, targeting the S3 nerve 
root which is identified as the most relevant home for impulses, containing sensory 
fibers from the pelvic floor and parasympathetic neural fibers affecting the detru-
sor muscle of the bladder. This differs from the target of other neuromodulation 
modalities, and provides a distinct pattern of identification during implantation, 
which will be discussed later [14, 15].
2.2.1 Mechanism of action
The goal of SNM is to modulate abnormal bladder sensations the patient may 
have, as well as involuntary uncontrollable reflexes in the lower urinary tract to 
restore the patient’s voluntary control and facilitate normal function [16]. The 
theories on how it actually achieves these goals are vast, and expanding to date, 
and remain complex. This is perhaps in part due to the sophisticated interaction 
of higher central voiding centers in the brain and spinal cord and the peripheral 
nervous system in facilitating the functions of the lower urinary tract.
Investigators have assessed a multitude of concepts, from the molecular neu-
rophysiological level to broader neurocirculatory behaviors in the brain and spine, 
in both animal models and human studies. Yet to date, no single theorem has been 
solely agreed upon. Some studies have even shown dual or multiple mechanisms 
through different channels by which SNM exerts its modulatory effect on the lower 
urinary tract, partly by studying its different effects in many neuro-urological 
conditions ranging from bladder overactivity to chronic pelvic pain.
SNM therapeutic effects are speculated to arise through electric stimulation of 
both afferent and efferent neural circuits in the pelvic viscera and connections with 
spinal interneurons. The stimulator produces an electrical charge in close proximity 
to the sacral root nerves, regenerating propagational axonal action potentials in the 
region. This in turn stimulates somatic afferents which modulate higher center con-
trol of micturition including the prefrontal cortex and insula, by restoring normal 
bladder function and perhaps suppressing reflex bladder activity such as that seen in 
overactive bladder (OAB). This indirect effect both on the bladder and the urinary 
sphincter is achieved through adaptive neural plasticity, and thus, an intact neural 
system, at least distally, is a neural requirement for SNM to successfully restore 
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bladder function [15–21]. The SNM device can provide different levels of stimula-
tion, which may further modulate efferents to the bladder-sphincter complex; 
however, it does not have any direct effect on urethral resistance [16, 22].
Several studies have proved that SNM has modulatory effects in the brain. 
Earlier work has demonstrated stimulatory and inhibitory effects in specific brain 
regions including those responsible for alertness, sensation of bladder filling, and 
timing of micturition [23, 24]. Utilizing positron emission tomography (PET) and 
functional magnetic resonance imaging (fMRI) of the brain, researchers were able 
to identify decreased function after SNM in areas like the orbitofrontal cortex, 
angulate gyrus, and thalamus, while stimulating the dorsolateral prefrontal cortex, 
and the therapeutic effect of SNM corresponded to pre-implantation increased 
activity in the angulate and inferior frontal gyri, insula and thalamus. Such pat-
terns of activity in the brain were shown to predict response to SNM treatment 
in females with OAB. Furthermore, investigators were able to show that different 
SNM stimulus intensities had varied brain responses, which may have differential 
therapeutic implications [23–27].
On the neurophysiological level, much has been investigated to understand 
which neural receptors and neurotransmitters may be affected by neuromodula-
tion, SNM in particular. Opiod receptors are shown to be inhibited by SNM, and 
this inhibitory effect is augmented by tramadol and other opiod receptor agonists 
[28]. From animal models, blockade of opiod receptors with naloxone significantly 
reduced bladder capacity during sacral neuromodulation for reflex bladder activity. 
Blockade of beta-2 receptors, however, showed the opposite response during SNM 
[29]. Also mediated by opiod receptors are the SNM inhibitory effects of bladder 
overactivity mediated by supraspinal GABAA receptors [30].
2.2.2 Indications and contraindications
2.2.2.1 FDA approved indications
The US Food and Drug Administration has approved four main indications for 
SNM application, three of which are urological: refractory urinary urgency and 
frequency, urge urinary incontinence (UUI), non-obstructive urinary retention 
(NOUR), and lastly, fecal incontinence. This has been agreed upon and resounded 
by multiple authorities including the International Continence Society in their 
best practice statements, among other bodies [4]. However, FDA approval does 
not indicate level of recommendation, and authoritarians and experts in the field 
have built on this approval to debate and set the grade and the line of therapy at 
which SNM serves for a number of conditions, as well as argue for and against other 
indications or applications the FDA has not seen the benefit of SNM for eye-to-eye 
with available literature and results. There are, moreover, conditions that must be 
met prior to justifying an implantation regardless of the aforementioned indications 
and contraindications that must be observed.
The International Continence Society (ICS) assessed the evidence available for 
SNM in different pathological genitourinary conditions and published its recom-
mendations based on available literature. In summary, the ICS panel found grade A 
evidence to support the efficacy of SNM in overactive bladder and non-obstructive 
urinary retention including Fowler’s syndrome and voiding dysfunction; however, 
this high level evidence did not change their recommendation of maintaining SNM 
as a second or third-line mode of therapy in these disorders. For other conditions 
including interstitial cystitis/bladder pain syndrome (IC/BPS) and neurogenic 
lower urinary tract symptoms, SNM remained an option based on lower levels of 
evidence (grade C evidence/level III recommendations) [4, 31].
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2.2.2.2 Off-label uses
Although the FDA has not recognized or approved these applications of SNM, 
there is a growing body of evidence that demonstrates its effectiveness in other 
genitourinary pathological conditions. In particular are chronic pelvic pain disorders 
including both IC/BPS and non-IC chronic pelvic pain syndrome (CPPS). Despite 
lack of availability of high-level evidence, the off-label application of SNM in these 
conditions continues with variable results in improving associated urinary symp-
toms and quality of life parameters.
Other non-approved applications of SNM include its use in special popula-
tions such as those with neurogenic lower urinary tract symptoms, pediatrics and 
adolescents, and even in contraindicated situations including continued SNM in 
pregnancy for women with urological conditions. Most of these applications carry 
hypothetical risks, a spectrum of which have been refuted in small case series and 
reports in literature, but bigger studies are needed to elucidate and clarify the role 
of SNM in these situations.
2.2.2.3 Contraindications
Authorities have agreed on certain absolute and relative contraindications for 
SNM [4], with exceptions and points up for debate to date in the literature.
Absolute contraindications of SNM are:
1. An inadequate clinical response—this is dictated by the universally accepted 
cut-off of more than 50% improvement during the test phase of SNM.
2. The patient’s inability to operate the SNM device, or lack of caregiver support 
thereof who could assist in doing so.
3. Pregnancy, and this remains a point of debate across literature, as will be 
discussed further next.
The relative contraindications for SNM therapy, as outlined by many guidelines 
including the ICS best practice statements, do not preclude use of SNM, but must be 
vigilantly observed and discussed with the patient prior to embarking on treatment. 
These include:
1. Severe and/or rapidly progressive neurologic disease with urinary symptoms—
in such a state, the patient’s foreseeable benefit from treatment, even based 
on a successful test phase, would be challenged by the changing neurological 
status or development and progression of the disease.
2. Complete SCI, which would hinder the modulatory effect of SNM in higher 
nervous centers as discussed earlier.
3. The ongoing recognized or observed need for magnetic resonance imaging 
(MRI) examination, particularly in patients with established neurological 
disorders like multiple sclerosis (MS) that may need continued MRI assess-
ment or patients undergoing work-up for other conditions that may need 
it, particularly non-head MRI examination, which will be discussed further 
in a separate segment as growing reports continue to argue MRI safety with 
implanted SNM devices.
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4. Abnormal sacral anatomy is a sensible contraindication in which such deformi-
ties would hinder the identification of the correct sacral foramens required for 
optimum effect and implantation.
2.2.2.4 Magnetic resonance imaging
With the exception of head MRI examination, the ongoing or anticipated 
need for MRI examination for patients is a relative contraindication for SNM 
implantation [4, 32]. The potential effect of non-head MRI examinations on 
an implantable metallic device such as SNM have debilitated practitioners and 
potential patients alike with one series reporting that 23% of device explanta-
tions at their center were due to the need of the patient to undergo this examina-
tion. This has absurd financial and clinical implications in the face of an effective 
implantation [33].
In the same series, two thirds of the explanted patients required a change in 
management post-explantation, including intradetrusor botulinum injections, or 
to resort to self-intermittent urinary catheterization or even require in one case 
cystectomy and urinary diversion. Thus, explantation has dire consequences that 
must be outweighed against the potential need and risks of undergoing MRI espe-
cially when over 20% of the patients that were explanted prior to MRI examination 
ended up not undergoing the imaging test and just over 50% of those MRI results 
influenced non-genitourinary treatment decision making [33]. Additionally, one 
cannot help but wonder the number of patients who may have benefitted from SNM 
therapy had they not been excluded due to prospective need for MRI with better 
and alternative planning.
2.2.2.5 Pregnancy
It is difficult to design trials to test for the effects of SNM, or any form of 
neuromodulation or therapy for that matter, when there is a hypothesis of poten-
tial teratogenic effect on the fetus, or risk of abortion or premature delivery. 
Apart from the overridden potential for damage to the SNM system when it was 
historically being implanted in the anterior abdominal wall, completely posterior 
SNM implants or their predecessors have not been shown in a number of series 
and reviews to be associated with any fetal malformations or early deliveries or 
a higher rate of cesarean sections. These reports are based on pregnant women 
who against recommendation and electively opted to maintain their SNM devices 
on during their pregnancies fully or at certain periods and trimesters [34, 35].
Thus, the decision to continue neuromodulation, or to proceed with implanta-
tion for a woman who has not completed her family or is actively trying to conceive, 
remains a debatable and individualized decision, but in accordance with manufac-
turer recommendations and societal guidelines and until more compelling evidence 
arises, pregnancy will remain a contraindication for SNM, though more relatedly 
relevant than absolute [34].
2.2.2.6 Other considerations
Potential interference of SNM devices with other implantable electrostimula-
tors such as cardiac pacemakers has long been speculated. A series of three patients 
who have cardiac pacemakers and underwent SNM implantation has reported that 
no interference was observed on the part of either of the implanted devices by the 
other [36].
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2.2.3 Predictors of effect
One of the hallmarks of diagnosis of urinary and voiding dysfunction disorders 
is the utility of urodynamic testing (UDS). Of different types and modes, this 
diagnostic test aims at reproducing patient symptoms and correlating them to net 
intradetrusor pressure, among other parameters, in simulated bladder filling and 
voiding phases. Much has been disputed about the need for UDS testing to diagnose 
straightforward and clinically apparent conditions such as overactive bladder, and 
whether UDS findings could help predict outcomes of therapy including SNM prior 
to its implantation. However, evidence suggests that no single UDS parameter or 
finding can predict SNM success [37].
In its best practice statement, the ICS did not find sufficient evidence to sup-
port that urodynamic studies can predict outcomes of treatment for SNM, while 
it supported based on higher level of evidence a stronger recommendation for 
performing SNM trial phases as the “single most valuable tool” to predict outcome 
of SNM [4].
Attention has been given to difference in SNM effects between certain patient 
populations. Gender differences have been long hypothesized, with attention 
focusing on SNM effects on pelvic floor rehabilitation and its close relatedness to 
urinary and chronic pelvic disorders in females as a potential modality of effect. 
In a matched pair analysis, a group of researchers reported on 80 patients who 
received SNM implants for urge urinary incontinence and found that more women 
tended to receive implants than men. While urinary frequency and symptom scores 
improved in both groups, over 3 years, the number of urge incontinence episodes 
per day improved in men more than women, while the severity of the incontinence 
improved in women more than men [38]. This gender discrepancy may be explained 
in part by SNM effect, but perhaps is also due to anatomical difference of the distal 
urinary tract in men and women.
Another patient population suspected to be at a lesser advantage from SNM 
efficacy are older patients and those with certain comorbidities such as obesity. 
Interestingly, one study did not only find no difference in response among older 
patients but further identified that age correlated with a lower rate of surgical revi-
sions of the implantation—3% lower odds per year. In the same study, BMI did not 
influence explantation rates [39].
It is undeniable that there are identifiable structural changes in the bladder mus-
cle and wall that incur from long standing overactive bladder and non-obstructive 
urinary retention, and hypotheses suggest this may affect the therapeutic outcomes 
of SNM as the symptom duration increases. However, even symptoms extending for 
more than 10 years have not been shown to have any significant effect on the success 
of SNM [40].
2.2.4 Results of SNM and its efficacy
SNM has proven an efficacious modality of treatment of different genitouri-
nary disorders, with durable success rates between 70 to 80% in certain conditions 
such as refractory OAB [11, 31, 41, 42]. In one survey of SNM patients, satisfac-
tion rates were reported to be over 95% with SNM therapy and were not affected 
by patient age or any complications or program type, a testament to the efficacy 
of this treatment [43]. The multitude of data in the literature also attests to the 
general safety of SNM [44].
History of prior back surgery may be deemed a challenging patient condition for 
SNM implantation, but a review of 500 patients has shown that such a history did not 
negatively affect SNM outcomes [45]. Even in patients with prior anti-incontinence 
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surgery and history of pelvic organ prolapse surgery, the efficacy of SNM has been 
established. Surgeries of the bladder and pelvic floor may slightly affect the outcomes 
of SNM, however, these remain generally good and acceptable [46].
2.2.5 Cost-effectiveness
The debate continues on what is the cost-effectiveness of SNM compared to 
other available treatments for refractory voiding conditions be it OAB or UUI or 
others. These include in general combination medication, intradetrusor botulinum 
injections (repeated as the effect of one injection wears out necessitating periodic 
repeat injections), and more definite bladder or anti-incontinence surgeries.
The long term outcomes of SNM compared to the need for maximal medical 
therapy or repeated botulinum injections poses a cost-effective benefit superior 
to the aforementioned counterparts, with some authors even arguing that from 
a patient’s perspective it may well be considered an appropriate primary therapy 
rather than a second or third line alternative [47]. Compared to botulinum injec-
tions in particular, SNM was shown in one study to be cost-effective from the third 
year of application onwards, with a clear dominance should treatment be continued 
for 10 years [48]. However, results from the ROSETTA randomized trial which 
compared SNM and botulinum bladder injections for refractory UUI showed SNM 
as a less cost-effective alternative [49].
Perhaps the arguments for and against the cost-effectiveness of SNM versus 
other treatments lay not just in the treatments it is being compared to but in terms 
of what condition these treatments are being utilized for. In a focus article on safety 
and cost of SNM compared to botulinum injections for OAB, although SNM was 
costlier, it was safer than intradetrusor botulinum injections. The latter carries a 
substantial side effect profile including urinary tract infections, hematuria, urinary 
retention, and more frequent emergency room visits, all not common occurrences, 
but may tip the scale in favor of SNM [50].
2.2.6 Preoperative assessment and counseling
As with any surgical procedure, preoperative assessment and counseling are 
of paramount importance. It has been identified that such counseling should 
include discussions on possible expected side effects and adverse events of SNM 
therapy, such as implant site pain, infection, paresthesia, and leg and buttock pain. 
Moreover, the patient must understand that within the spectrum of approved 
devices in clinical practice, currently the Interstim® device in its two generations, 
there may arise a need for surgical revision of the implant or ongoing reprogram-
ming atop an eminent and eventual need for replacement of the implantable pulse 
generator (IPG) once the battery wears out should treatment extend beyond an 
expected life-expectancy of 3 to 5 years on average. Additionally, and based on ICS 
recommendations, urodynamic testing is not mandatory, but phase testing is highly 
recommended prior to embarking on surgical implantation of the SNM IPG [4, 51].
One side effect profile that has been raised in the literature has been the psycho-
logical aspects of SNM therapy, though some authors have argued that a reverse 
pathology is possible with patients with chronic genitourinary and pelvic pain dis-
orders who are potential candidates for SNM are pre-operatively burdened or have 
pre-existing psychological ailments. As is the limited evidence from some case reports 
and series, some patients encounter behavioral changes or exacerbation of preexisting 
psychological conditions such as depression, which has led to the argument of need 
for psychological assessment of certain traits that may affect SNM outcomes [52]. 
However, this has yet to be reflected in the guidelines and societal recommendations 
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and a causality has not been established. On the other hand, other researchers have 
shown no influence of psychological and psychiatric factors on SNM outcomes [53].
2.2.6.1 General considerations
SNM implantation requires, most commonly, fluoroscopic guidance in the lead 
placement stage of the procedure to correctly identify the S3 foramen and the depth of 
lead placement and direction and correlate it with the reflex responses of the patient. 
Though of ongoing concern, studies have shown that radiation during SNM implanta-
tion, be it staged or office-based percutaneous nerve evaluation (PNE), is safe and 
within the recommended limits set by the International Commission on Radiological 
Protection [54]. That, however, did not alter an ongoing debate on whether “fluoro-
guidance” can be replaced by a less radioactive imaging modality, the ultrasound. 
Apart from having a far lower radiation exposure profile, if any, ultrasound-guided 
lead placement was found in one study to lower the number of needle punctures 
needed to identify the most suitable S3 foramen for patient response; however, that 
had minimal effects on total operative time [55].
Preoperative antibiotic administration is also advocated in both stages of implanta-
tion. The recommended antibiotic regimens should target common skin flora patho-
gens. Guidelines published by the French Association of Urology suggest the use of 
amoxycillin or broad-spectrum cephalosporins, and in case of hypersensitivity to these 
antibiotics, an alternative combination of vancomycin and clindamycin is suitable [56].
2.2.7 Technical aspects and techniques
2.2.7.1 The device: lead and implantable pulse generator
The SNM device consists of a tinned lead, connected to a stimulator, the 
implantable pulse generator (IPG), by insulated cords. Improvements have been 
made between the initial and current Interstim II device available on the market, 
including the tinned lead technology, deflected lead tip, and increased capacity of 
storage of programming and patient data, among others.
The tines allow for anchorage of the lead and prevent displacement. The 
quadripolar lead contains four electrical stimulation contact regions or electrodes, 
which are used to designate four different programmable charges on each region 
to provide an endless number of possible combinations of modulatory programs 
for patients for a variety of symptoms and effects. These are under the control of 
an external programming remote that allows the surgeon or programmer to store 
certain programs to the system of the patient. The patient can then use their own 
remote to initiate or shutdown certain programs at different times, or switch off the 
device all together, as well as control the intensity of the stimulation. An illustration 
of the quadripolar tinned lead can be seen in Figure 1.
The IPG is a battery-dependent neuromodulator that delivers electrical stimula-
tion transmitted via the lead. It has an embedded antenna that receives signals from 
the operator remote controllers [42].
2.2.7.2 Office-based percutaneous nerve evaluation
This modality of lead testing or screening for possible responses is done in the 
office setting under local anesthesia and allows assessment of both sensory and 
motor responses of the patient to stimulation. It can be done under fluoroscopy or 
ultrasound guidance. It is deemed a less invasive and less resource-intensive testing 
phase prior to implantation. However, it is more uncomfortable to the patient since 
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only local anesthesia is being used [57]. As a matter of fact, single-staged implanta-
tion after PNE could save US $1500–5000 depending on how high the success rate 
of the implantation is, an argument well utilized on part of advocates at both ends 
of the debate of whether to stage or not [58].
Local anesthesia is applied subcutaneously to the mid-sacral region where testing 
will be performed. In the prone position, a needle harboring a single-electrode lead 
is advanced to correctly identify the S3 foramen. The S3 foramen can be identified 
fluoroscopically, or approximated anatomically as evident from cadaveric studies 
that showed the mean distance of the superior aspect of the S3 foramen is approxi-
mately 9 cm from the coccyx, and laterally it is 2 cm from the middle of the sacral 
back region, while vertical interforamenal spaces are around 1.5 cm in length [59].
The patient is asked to report any sensations felt in the perineal region or 
the foot, and motor responses are also examined in the buttock region and the 
ipsilateral foot. Stimulation is then performed at different voltages and the area 
is marked. Successful office-based PNE is followed by one-stage surgical tinned 
4-electrode lead placement and IPG implantation. Motor responses are rechecked 
during implantation, and location and laterality may be modified to obtain the most 
appropriate response. This is probably one of the most important disadvantages and 
arguments against PNE in favor of staged implantation: bypassing a longer assess-
ment or testing period that would reveal more information about the prospective 
efficacy of the chosen S3 foramen and SNM implant.
The ideal patient for PNE is a cooperative and apprehensive one who can remain 
relaxed during the procedure. Patients who cannot lay prone for any reason or 
medical condition, and those who may need more deeper stimulation such as those 
morbidly obese or anyone with anatomical variations or previous sacral scars may 
preclude office-based PNE [57]. However, in one study by Gonssen and colleagues, 
the need for general anesthesia was substituted by a complete permanent SNM 
implantation under local anesthesia, and was reported to be both safe and tolerable 
with successful outcomes [60].
Focus has been given in current research and modifications of leads to replace 
current PNE leads with more functional multipolar leads that would allow a more 
idealistic response and minimal manipulation of the lead [57].
2.2.7.3 Stage I testing of two-stage implantation
Under sedation or general anesthesia should the patient require it if they can-
not maintain an airway in the prone position, staged SNM implantation depends 
Figure 1. 
Quadripolar tinned lead utilized in SNM. Labeled are the electrode positions, “0” being most distal and “3” 
most proximal. An optimum insertion is eliciting a response on all electrodes at low voltage.
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on a primary stage I of testing done in the operative theater where the tinned lead 
is eventually implanted after eliciting the best motor response and insulated cord 
cables are tracked to the contralateral side and eventually out of the skin to be con-
nected to a temporary pulse generator for the testing phase. These cables are later 
re-tunneled back the ipsilateral side where the tinned leads have been implanted 
and are connected to the implantable IPG.
This is the method utilized at our center, where we deem it and it has been proven 
to be more comfortable for the patient in a controlled setting where even sedation 
can be switched to anesthesia should the patient become restless. Nevertheless, 
muscle relaxation is not administered to maintain the ability to assess motor 
response on lead placement and testing. One particular population of patients which 
are ideal candidates for this mode of testing are morbidly obese patients where local 
anesthesia administered subcutaneously may not be sufficient for the deep layer 
manipulation necessary to deliver the lead to the sacral foramens [57].
Some researchers have continuously advocated staged testing and implanta-
tion despite PNE being a more resourceful alternative. Arguments included the 
increased comfort of the patient allows for better identification of ideal patients for 
therapy and less likely to result in a misleading positive screening but unsuccessful 
subsequent implantation. It also allows the employment of a longer testing trial 
period and has the added potential of fine-tuning stimulation parameters. It has 
been advocated as the ideal modality of screening for responses in patients with 
NOUR, sensory urgency and CPPS [57].
The two-stage implantation technique depends on a 2–4 weeks arbitrary period 
of testing for improved responses in patients planned for implantation. This period 
has been contested in literature, as are the arguments in favor of office-based 
PNE. The range of reported successful test phases is around 60% [61]. However, the 
length of this period has been also up for debate. One group of researchers studied 
a group of patients who underwent stage I SNM implantation test phase and found 
that the mean time needed to identify potential successful outcomes of the test was 
3 days, ranging from 1 to 9 days in total. This was not different between patients 
implanted for OAB and those for NOUR, and thus they concluded that a test stage I 
period of two or more weeks may not be necessary [61].
The importance of such an argument lays in the potential morbidities of a pro-
longed test period, with partially exposed external leads liable for displacement and 
a possible route for infection, though the literature does not report on either. The 
length of stage I has been suspected to be a risk factor for SNM implant infections, 
but the evidence is lacking, and the identifiable association if any may be the result 
of improper antibiotic regimens or assessment of small sample sizes of patients [62].
Disadvantages of staged screening and implantation include that only motor 
responses are assessed during lead placement. Sensory responses cannot be assessed 
in the presence of even light sedation. However, two formal studies have found that 
motor responses more importantly surpass sensory responses in predicting SNM 
successful outcomes [57]. These are in addition to the logical added financial and 
time requirements for testing in the operation theater and the need for anesthesia.
2.2.7.4 Lead placement
In SNM, the lead is placed in the S3 foramen, either on the right or left side, and 
rarely bilateral lead placement is undertaken. The S3 foramen has been identified 
to be relevant to the target nerve fibers required to achieve the effect of SNM [15]. 
Patients exhibit and experience typical motor and sensory responses to lead place-
ment in the S3 foramen, depending on the setting of lead placement under local or 
general anesthesia. This is further summarized in Table 1, along with responses 
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of adjacent S2 and S4 foramens, which surgeons utilize to correctly identify the S3 
foramen and avoid the formers [63, 64].
The placement of the actual tinned lead is preceded by testing or screening using a 
conductive long needle that is introduced first in the correct foramen, and a conductor 
is used to elicit the best response possible on the most number of electrodes (optimum 
being four-out-of-four positive electrodes at the lowest stimulatory voltage possible). 
Once finalized, a small skin incision around the needle facilitates for the introduction 
of the tinned lead in the chosen foramen. This tracking is aided by an introducer stylet 
[42, 63, 65, 66]. Figures 2–5 show an illustration of the steps on the introduction of 
the tinned lead and implantation of the IPG, while Figure 6 shows how the inserted 
tinned lead looks like and is confirmed to be correctly placed on fluoroscopy.
There is no agreed upon definition of optimal lead placement, and many factors 
have been speculated to alter placement and SNM outcomes, including position 
and depth of lead, angle, and deflection (straight, lateral or medial related to the 
foramen), but none shown to have any relation to SNM outcome. Lateral deflection 
is the only factor found to be associated with identifying more active electrodes, 
although the number of active electrodes itself has not been shown to correlate with 
a better motor response. Thus, the concentration during lead placement especially 
under general anesthesia should be on identifying the best motor response rather 
than on anatomical details [67].
In the quest for optimal lead positioning and how to facilitate this process, some 
researchers have advocated for the use of a curved stylet during the introduction of 
Foramen Sensory response Motor response
S2 Buttock sensation
Leg sensation
Foot: plantar flexion, foot rotation
Anal sphincter “clamp movement”
S3 Perineal paresthesia or pulling sensation in rectum, 
scrotum or vagina
Anal bellows “winking”
Great toe dorsiflexion
S4 Pulling sensation in rectum only Anal bellows only without leg or 
foot movement
Hubsher et al. [63] and Thompson et al. [64].
Table 1. 
Expected responses from SNM at different sacral levels.
Figure 2. 
Test needle insertion into the S3 foramen. The needle position is confirmed fluoroscopically or by ultrasound. 
An electrostimulation probe is then used in contact with the distal end of the needle to test for appropriate 
motor responses.
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Figure 4. 
Tined lead position after removing of stylet and introductory sheath. Note position of electrodes deep to foramen 
and in proximity to nerve root.
Figure 5. 
Final position of implanted pulse generator (IPG) and connections.
Figure 3. 
Introductory stylet inserted in chosen S3 foramen. The stylet guides enclosed lead. Once removed, tines allow for 
anchorage of lead in proper position.
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the tinned lead into the foramen. The tip of this stylet has an 18° bend that allows 
it to follow the natural pathway of the sacral root nerve. This is thought to allow for 
identification of an ideal response on all 4 electrodes at low voltage, subsequently 
providing greater flexibility with programming [68].
During lead placement and testing, the requirement is not only limited to correct 
identification of the S3 foramen, but also to eliciting the best response from the 
patient on stimulation at the lowest voltage possible. Researchers have argued for 
years for unilateral or bilateral lead testing. What is evident from studies to date is 
that the side that tests with the best motor response (or sensory response if patient 
can relay it) does not necessarily translate into the best outcome for therapy on 
the long-term. However, bilateral testing has the advantage of allowing patients to 
choose the side that they find more beneficial or comfortable [57].
2.2.7.5 Implantation of internal pulse generator/stage II procedure
Implantation of the internal or implantable pulse generator (IPG) can be in the 
setting of a single-stage along with lead placement following successful PNE testing, 
or the second stage of a staged implantation after a successful trial period following 
stage I lead implantation. Regardless of the staging, the IPG is implanted in a subcu-
taneous pocket on the same side the tinned lead has been placed in the S3 foramen. 
Sterility of the IPG device must be maintained to avoid acute or chronic infections.
After skin preparation and administration of necessary local anesthesia, a 
subcutaneous pocket is created under the skin in the patient’s buttock. This pocket 
should be high enough away from the seating area of the patient, and deep enough 
to avoid superficial sensation of the IPG by the patient as well. Preoperative mark-
ing is helpful in such scenarios, keeping in mind distance from the employed S3 
foramen as well to avoid tension on the connection between the tinned lead and the 
IPG. The cord is tunneled from the lead to the IPG subcutaneously and the connec-
tions are made. Before wound closure, wash with a sterile water-based antibiotic 
solution has been described by some authors. It is important to avoid saline-based 
solutions that may cause electronic malfunction of the device [41, 42, 63, 65, 69].
2.2.8 Post-implantation programming and troubleshooting
Programming is done after IPG implantation when the patient is fully awake and 
conscious to provide feedback on different modes and programs as they are being 
Figure 6. 
Fluoroscopic confirmation of position of lead and electrodes in relation to sacral spine.
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tested and tried out and allows them to choose their preferred settings. At our cen-
ter this is done on the next day postoperatively and ensues removal of the urinary 
catheter placed during the procedure to allow for trials of voiding [41, 70]. Patient 
follow-up is periodic thereafter, during which voiding and stimulation parameters 
are checked and patient compliance is evaluated [42].
Good communication between the patient, surgeon and the programmer are nec-
essary to obtain the optimum results and efficacy of SNM. In cases where any unfore-
seeable event occurs, such as sudden loss of efficacy or any of the adverse events that 
will be discussed as follows, proper testing of the programs and circuit impedance, as 
well as efforts at reprogramming operational electrodes should be utilized extensively 
before reaching the morbid decision of revision or explantation [42, 71, 72].
2.2.9 Adverse events and complications
Adverse events associated with SNM are numerous and well-documented. The 
majority of such events are anticipated and even counseled for preoperatively, with 
a documented range of 16–30% between the test and final implantation stages. 
Unanticipated or unexpected adverse events and complications are rare and are 
limited to isolated case reports and limited series [73].
2.2.9.1 Pain
Implant site pain is pain perceived at the site of the IPG. This could be the result 
of many reasons. A too-superficial implant may be cutaneously felt and pose a 
source of discomfort especially if implanted at a lower gluteal point and as such 
would be “sat on” by the patient. In one review, the most commonly cited reason 
for explantation was site pain [74]. Another series reported this to occur in 7% of 
implants, with the majority presenting beyond 30 days of implantation and some 
associated with trauma.
Another cause of pain could be stimulation program related. Turning off the 
IPG can differentiate between IPG-related and program-related pain, the latter 
usually requiring changes in stimulator settings by the programmer [42]. In the 
most debilitating cases, and often, this complaint would require surgical revision 
of the pocket or implant [73].
Pain could also be felt at the site where the stimulatory sensation is perceived, 
and this too, could often be differentiated by turning off the stimulator, and subse-
quently altering the settings [42].
2.2.9.2 Undesirable change in stimulation
Perhaps one of the most unfortunate adverse events is an undesirable change in 
stimulation that leads to loss of a successful SNM effect or subjective dissatisfac-
tion with an objectively successful implant. In one series, researchers reported this 
to occur in 12% of their surveyed adverse events in SNM implants for OAB. The 
majority of such incidences can be corrected with simple or sometimes more 
complex reprogramming of the neuromodulator, and rarely requires revision or 
explantation [73]. However, decrease in efficacy of stimulation is a major reason for 
reoperation and explantation should reprogramming in absence of lead migration 
fail to correct the deficiency [42, 75].
Checking the impedance can be useful to assess for any possible lead breakage or 
dislodgement which would show high impedance, but if the impedance is less than 
50 ohms, this may indicate a short circuit that could be due to a wet connection. 
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Reprogramming electrodes with acceptable impedances could provide a temporary 
or alternative solution, but lead revision is often necessary [71].
2.2.9.3 Implant infection
In a multicenter retrospective case–control assessment of risk factors for explan-
tation of the SNM device due to infection, researchers reported on an almost 2–3% 
incidence of infection and identified that hematoma formation and IPG pocket depth 
of greater than 3 cm were independently associated with development of infec-
tion, while implant infection was the leading cause of device explantation at 1 year 
follow-up in another large trial [68, 73, 76]. The most common pathogen reported on 
cultures obtained from these explants was the skin flora resident S. aureus. Infection 
is probable both early in the postoperative period within 30 days of implantation, or 
later beyond 30 days and sometimes up to 10 months post-implantation [73, 76].
Risk factors associated with SNM implantation infection have been studied, and 
some have been refuted. The choice of preoperative antibiotic regimen is of impor-
tance in both stage I and final IPG implant, and the antibiotic administered should 
target potential and common skin organisms such as S. aureus [62].
Prevention of such infections has also been reviewed. One group of researchers 
reported on the use of an antibiotic-coated collagen layer placed over the IPG before 
wound closure with noticeable results. Skin preparation is also important, particu-
larly with chlorhexidine-based solutions per international recommendations [62, 68]. 
And although many surgeons still do administer certain courses of post-implantation 
antibiotics, this is not supported by any clinical evidence of benefit, though further 
research may better define its role as is the case with other prosthetic or implantable 
devices [62].
2.2.9.4 Lead fracture and displacement
Lead fracture, migration or dislodgement are a rare occurrence reported at 
around 1% of adverse events and eminent needs for device and lead replacements. 
The introduction of the tinned leads has aided in lowering the incidence of lead 
migration [41].
Patients may have, against better judgment and counseling, engaged electively in 
physically demanding exercises, or it may be the result of sudden acute movements 
or trauma. The result is a sudden loss of or major change in stimulation. On testing, 
high impedance (>4000 ohms) is found on all 4 electrodes [73]. Additionally, sacral 
x-ray imaging can help determine if any lead displacement or dislodgement is pres-
ent. If evident, especially in the presence of complete loss of efficacy and all other 
alternative reprogramming efforts have been extorted, replacement of the lead is 
necessary, and sometimes contralateral placement or even bilateral stimulation may 
be needed, though the latter may not always prove successful [42, 71, 77].
2.2.9.5 Unanticipated adverse events and complications
It is important to understand that although rare, complications are an important 
predictor of SNM reoperation and may result in severe morbidity [75, 78]. Rare 
complications of lead placement and implantation have been reported in separate 
case reports and limited series, including one case of retroperitoneal hemorrhage 
after SNM implanted for urge incontinence [79]. Another case of lead migration 
into the sigmoid colon during implantation was complicated by and presented as a 
colocutaneous fistula [80].
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2.3 Direct PNS
As our understanding grew of the neurological contribution and circuits from the 
sacral nerve roots, new-found focus has been on stimulation of the whole pudendal 
nerve as it originates from its S2, S3 and S4 nerve roots, and not just the S3 nerve 
root as with SNM. Theoretically, this should provide a more inclusive sacral nerve 
stimulation than targeting S3 alone, resulting in inhibition of the micturition reflex 
and controlling uninhibited detrusor contractions while increasing bladder capacity 
[14]. This was the hypothesis of the early work on PNS, proposing it would particu-
larly benefit neurogenic bladder patients who fared less successfully with SNM [5].
By placement of both a sacral and pudendal tinned leads in Alcock’s canal either 
tranperineally or through a posterior approach, continuous electrical stimulation 
similar to SNM is delivered to both nerves [5]. One group of researchers demon-
strated comparable improvements in voiding parameters between the PNS and SNM 
groups, but subjective superiority for PNS reported by patients [81]. PNS was not 
only found to improve continence but increase bladder capacity in neurogenic blad-
der patients [5]. Another variation of pudendal PNS is dorsal genital nerve stimula-
tion (DGN), the pudendal nerve’s most anterior branch, and this may be the next 
therapeutic alternative [5, 82].
2.4 Peripheral, cutaneous and minimally invasive neuromodulation modalities
Bypassing the need for formal implantation of any device, these varied modali-
ties of neuromodulation employ concepts on transmitted electrical stimulatory 
signals from the skin to the nerve vicinity or from peripheral nerves to more central 
sacral nerve roots and in turn, resulting in a modulatory effect and control on reflex 
bladder activity particularly bladder hyperactivity, neurogenic or non.
2.4.1 Posterior tibial nerve stimulation
2.4.1.1 Mode of effect
Posterior tibial nerve stimulation (PTNS) provides indirect and retrograde 
electrical stimulation to the posterior tibial nerve as it passes posteriorly to the 
medial malleolus of the ankle; the posterior tibial nerve is a mixed nerve with roots 
from L4 to S3, and as such, provides its modulatory effects on sacral complex roots 
involved in the lower urinary tract through activation of somatic fibers and inhibit-
ing bladder contractions [1, 15, 83].
PTNS is performed by placement of a needle superoposteriorly to the medial 
malleolus and a grounding pad placed on the sole of the foot laterally (Figure 7). 
The needle is connected to the stimulator device, and low-voltage stimulation is 
applied: correct placement is confirmed when flexion of the greater toe is observed 
and the patient reports sensations from the sole of the foot [84]. Treatment sessions 
are repeated weekly for a period of 12 weeks and in 30-minute sessions. Repeat 
session cycles are possible [85].
One of the advantages of PTNS is a “carryover” effect. This has been described 
as continued symptomatic improvement not necessarily just during the nerve 
stimulation sessions, which is in contrast to the loss of efficacy when the SNM 
device is switched off. Many studies have examined the carryover effect and what 
implications it may have in devising PTNS regimens and schedules, with variable 
success [84, 86, 87].
Another advantage of PTNS is the fact it can be administered by any healthcare 
provider or the patient themselves after appropriate training. As a matter of fact, 
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home administration systems and micro implants are being developed for that sole 
purpose [84, 88]. PTNS, too, is less costly than SNM, on average [89, 90].
2.4.1.2 Predictors of PTNS success
In an effort to identify ideal candidates for PTNS treatment in OAB, a number 
of investigators identified that history of prior SNM therapy correlated negatively 
with PTNS outcomes. On the other hand, more severe complaints of urge urinary 
incontinence and urinary bladder volume at first sensation (a UDS parameter) were 
predictors of PTNS success [90].
2.4.1.3 Efficacy of PTNS
Efficacy of PTNS as evident from review of 4 randomized controlled trials, 
none of which pinned comparison against SNM, showed a majority of patients 
were able to achieve at least 50% improvement from baseline complaint; these 
studies ruled out the possibility of a hypothesized placebo effect, according to 
the reviewers. A substantial complaint from PTNS treatment was temporary foot 
pain [74].
Several trials have also compared PTNS to medical treatment of OAB, including 
the OrBIT trial, and reported comparable if not somewhat superior results with a 
lower side effect profile, particularly dry mouth and constipation among other side 
effects associated with anticholinergic medication [85, 91, 92].
2.4.2 Transcutaneous tibial nerve stimulation
Utilizing needles applied transcutaneously to stimulate the posterior tibial 
nerve, this modality of treatment has been investigated for MS and OAB patients 
[9]. There are limited studies that demonstrate variable improvements for OAB 
patients with transcutaneous tibial nerve stimulation (TTNS). Perhaps its advan-
tages stem from its safety and fairly minimal adverse events profile, and its low 
costs [93].
Figure 7. 
Posterior tibial nerve stimulation.
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2.4.3 Transcutaneous electrical nerve stimulation
As the name suggests, this modality is applied to areas in close proximity to 
target internal nerves. These include the pudendal nerve, be it through transcutane-
ous stimulation in the vagina in a female or in the perineal region in the male, or 
both the pudendal and sacral nerves when applied to the sacral skin. DGN is also a 
form of transcutaneous electrical nerve stimulation (TENS). It is advocated as a less 
invasive and low-cost neuromodulation system that can also be taught to patients 
for self-application [5].
Multiple small-sized trials have demonstrated improvements in symptom 
scores and efficacy in patients with refractory OAB or MS with bladder hyperac-
tivity. However, although it is safe, the durability of its effect has been called into 
question [9, 94].
3. Neuromodulation applications for urological conditions
3.1  Overactive bladder, urgency urinary incontinence and urgency-frequency 
syndromes
Bladder overactivity manifests in a number of urinary conditions, depending on 
the pathophysiology and associated conditions and symptoms. Overactive bladder 
(OAB), defined by a compelling frequent urge to void, is not a precession of urgency 
urinary incontinence (UUI), nor is it a more defined form urgency-frequency syn-
dromes: these are all an overlapping number of conditions where evidence of over-
activity of the detrusor muscle may or may not be demonstrable, but is subjectively 
reported by patients and often objectively measurable.
The treatment for these conditions is mainly conservative and medical, be it 
targeting the bladder muscle or the other offending factors that lead to the overac-
tivity, followed by intradetrusor botulinum injections, which has attained a more 
defined role in the OAB treatment scheme. SNM is an established mode of treatment 
for cases of OAB, UUI and urgency-frequency syndromes that are refractory to 
medical treatment, and despite arguments and established results and testaments, 
is yet to be designated a more primary or first line place in the treatment of these 
conditions [95].
3.1.1 Mode of effect in OAB
It has been shown that SNM has an established modulatory effect both on 
micturition reflexes and higher brain centers. The SNM electrical charging of sacral 
roots alters neural activity, stimulating somatic afferents that signal to higher brain 
centers and in part restore normal control over the bladder while also inhibiting 
certain sensory pathways to suppress reflex bladder hyperactivity. From animal 
models, evidence suggests this effect is achieved through SNM’s inhibition of 
abnormal sensory input from the pudendal nerve and neuropathological C-fibers, 
affecting release of μ-opiods and glutamate and suppressing bladder reflexes [16].
3.1.2 SNM efficacy in OAB
Efficacy of SNM is perhaps most studied and evidently reported in refractory 
OAB [96]. Analysis of five trials have analytically shown significantly higher success 
rates for SNM in treatment of OAB compared to standard medical treatment, and 
equally as efficacious as intradetrusor botulinum injections with less side effects 
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associated with the latter including risk of post-injection urinary retention and 
urinary tract infections [41, 74].
In one prospectively conducted multicenter trial on OAB patients, the 5-year 
success rate of SNM was 67%, with the most common adverse event or reason for 
failure demonstrated to be an undesirable change in stimulation, followed by site 
pain and ineffectiveness of treatment [97]. The InSite trial reported on one of the 
longest prospective follow-ups for SNM implants for refractory OAB. At 36-months 
follow-up, 83% of implants were found to have sustained efficacy [68].
3.2 Non-obstructive urinary retention and Fowler’s syndrome
Non-obstructive urinary retention (NOUR) is one of the main indications for 
SNM therapy. It denotes an unidentifiable mechanical cause that may obstruct 
urinary outflow from the urinary bladder, resulting in urinary retention. It may be 
the result of an established neurological disease, as is the case in the acute phase of 
spinal shock after spinal cord trauma, or in a minority of MS patients. Neither of 
these conditions are indicated for SNM treatment. However, chronic or recurrent 
urinary retention in a “neurologically-intact” patient is.
One form of NOUR is termed Fowler’s syndrome after the neurophysiologist 
Professor Clare J. Fowler who first described it in 1985. It is a cluster of symptoms 
and findings identified in a typically young woman with unexplained urinary 
retention, increased electromyographic activity of the external urinary sphincter 
and its failure to relax, and some associations to other female syndromes have been 
described including polycystic ovaries. Application of SNM in these patients has 
been shown to restore normal voiding activity [98].
3.2.1 Mode of effect
Researchers have used a number of animal models to establish the mode of effect 
SNM exerts in NOUR and Fowler’s. Basic science evidence suggests that by blocking 
the inhibitory effect that abnormal afferent activity from the external urethral and 
anal sphincters has on micturition, restoration of the ability of the patient to void 
occurs. This stimulation is through blockade of the pudendal nerve’s stimulatory 
effect of the micturition reflex [99].
3.3 Neurogenic lower urinary tract dysfunction
Lower urinary tract symptoms resulting from neurological disease are varied, and 
thus, determination of these symptoms and assessment is necessary before consid-
eration for neuromodulation as not all symptoms would be ideally treated using this 
modality. Neurological diseases that have documented voiding dysfunction elements 
include SCI, MS, Parkinson’s disease, cerebrovascular accidents, and diabetic neuropa-
thy. Congenital neurologic disorders such myelomeningoceles are becoming apparent 
causes of voiding dysfunction in adults and SNM candidates, as management of these 
pediatric disorders improves, and these patients grow into the adult population [9].
Previously thought to lack efficacy in neurogenic LUTD because of lack of an 
intact nervous system, SNM is emerging as an efficacious therapeutic modality for 
this population of patients especially in reducing incontinence episodes [9, 100–104]. 
The concept of neural remodeling as a hypothesized effect of SNM has also been 
visited as a potential role in neurogenic LUTD, particularly in acute spinal shock 
phases [9, 104].
The ICS recommends SNM as an option for control of urinary symptoms in 
patients with stable neurological conditions who are at a low risk of developing 
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upper tract deterioration from controlled voiding [4]. It is thus important to stress 
the need for proper assessment and continued evaluation of these patients as uri-
nary retention, acute or chronic, could have consequences including urinary tract 
infection and renal failure [9].
3.3.1 Spinal cord injury
SCI, especially complete transection, has long been accepted as a contraindica-
tion for sacral neuromodulation on the basis of a disturbed neural circuit. However, 
numerous reports have been reviewed that show promising results for SNM in 
the management of neurologically-stable SCI patients, even those with complete 
disruption [105]. In the acute phase of spinal shock where the bladder is atonic, 
SNM has been found to facilitate neurogenic remodeling as researchers theorize and 
demonstrate sustained SNM effects and remodeling in the brain [9, 104].
In a review of eight studies where SNM was employed in the management of 
lower urinary tract dysfunction in SCI patients, the success rate of the test phase 
was a shy 45%, but that later translated into a 75% success rate once the screened 
patients proceeded with IPG implantation. The treatment was well-tolerated and 
safe without any unexpected adverse events [106].
3.3.2 Multiple sclerosis
MS is of special interest to neuro-urologists as the disease manifests with a spec-
trum of urinary symptoms and progresses with different patterns in this spectrum 
along the course of the disorder as well. Demyelination, the pathological hallmark 
of MS, eventually affects lower urinary tract nerves, resulting in dysfunction. Up 
to 80% of patients show neuro-urological symptoms within 10 years of diagnosis, 
most frequently bladder overactivity. As a matter of fact, voiding dysfunction is the 
first sign of the disease in up to 10% of patients [107].
Though not FDA approved, neuromodulation has been applied in MS patients 
for years, and its efficacy has been repeatedly demonstrated. SNM and PTNS have 
been shown in a number of series to decrease urinary symptoms and improve the 
quality of life of MS patients who demonstrate bladder overactivity; however, 
although SNM is approved for NOUR, it has not shown any benefit for MS patients 
demonstrating “hypoactive” urinary bladders with retention [107, 108].
What remains an important issue for MS patients being considered for SNM is 
appropriate patient counseling and communication with their treating physician or 
neurologist to assess the need for MRI examination in the future as well as stability 
of the disease, as disease progression and relapse would negatively affect the SNM 
outcomes [9, 105, 107].
3.3.3 Diabetic cystopathy
Diabetic cystopathy is a condition that describes the neuromuscular effect 
long-standing diabetes has on the urinary bladder. Part of the condition stems 
from diabetic neuropathy, while another part may stem from vasculopathy 
affecting the detrusor muscle itself. In the application of neuromodulation to the 
control of overactivity symptoms resulting from diabetic cystopathy, promising 
results from series were overshadowed by a substantially higher than average rate 
of infections (17%) compared to the accepted average, as would be expected from 
any foreign body implantation in diabetic patients especially those with poor 
glycemic control [105].
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3.4 Special populations and effects
3.4.1 CPPS and IC/BPS
Chronic pelvic pain syndrome in males and its predominantly female counter-
part interstitial cystitis/bladder pain syndrome are chronic conditions of pelvic pain 
and voiding dysfunction with a poorly understood etiology [109]. Off-label use of 
SNM in the treatment of these disorders is established with significant results, and 
similar to its unknown etiology, the way SNM provides subjective and objective 
improvements in bladder pain syndrome for example is yet to be clearly defined, 
with obvious differences in outcomes between IC/BPS and non-IC/BPS CPPS [110].
Many theories have been suggested for this mode of effect, from restoration of 
balance between excitatory and inhibitory signals in the pelvic plexus at different 
spinal levels as well as SNM’s modulatory effect on bladder function and in turn 
pain. Another issue for consideration is the bilateral or multiple sacral root involve-
ment in bladder and pelvic pain disorders, thus S3 stimulation may be insufficient 
to providing symptomatic relief, and some researchers have demonstrated efficacy 
of bilateral stimulation [14].
A multitude of studies and researchers are reporting on promising results for 
SNM in symptomatic management of CPP disorders, demonstrating improvements 
in pain indices and quality of life measures particularly relating to improvements 
in sleep, social life and sexual activity [110, 111]. With 10% of patients of IC/BPS 
reaching a severe stage refractory to conservative and other modes of management, 
SNM has found an emerging role in the therapeutic void for this condition. Success 
rates of SNM in IC/BPS have been reported to be high, north of 80% in some series, 
with apparent and significant objective improvements in pelvic pain and specific 
interstitial cystitis symptom scores as well as improvements in daytime frequency, 
nocturia, urinary urgency, and average voided volume [112].
The ICS based on grade C evidence released a level III recommendation that 
designates SNM as an option for patients who are deemed non-responsive to 
conservative treatment measures of IC/BPS and non-IC CPPS [4]. However, large 
randomized controlled trials are lacking, perhaps in part due to the mixed spectrum 
of CPP disorders, both pathologically and symptomatically, heterogenous patient 
population, and unclear etiologies, and poorly understood differences in outcomes 
between the disorders [109, 110, 113].
3.4.2 Sexual function
The effects of neuromodulation, particularly SNM, on improving sexual func-
tion among female patients, and male patients to an extent, are becoming more 
evident in the literature [114]. Dysfunction of the pudendal nerve, an important 
nerve in sexual stimulation, has been demonstrated in both refractory OAB and 
NOUR [115].
In a cohort of female patients who received SNM implants for OAB, urgency-
frequency syndrome or NOUR, improvements in both female sexual function index 
and quality of life indices were reported, though they were not correlated [116]. 
In another study on SCI female patients who had sexual dysfunction, there was a 
demonstratable improvement in the female sexual distress scale after neuromodula-
tion therapy [117].
The argument is whether the improvements SNM provides with regards to uri-
nary symptoms allows for a better sexual experience and confidence among patients 
or does SNM’s effect on the pelvic floor musculature rejuvenise sexual function. 
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This argument is important in current applications and future considerations of 
neuromodulation for the treatment of sexual dysfunction. This was demonstrated 
in reviews of studies where sacral neuromodulation was employed in the treatment 
of neurogenic lower urinary tract symptoms and had demonstratable and maintain-
able improvements in erectile function indices to almost normal levels in a majority 
of patients after up to 3 years of follow-up [118].
On the contrary, another study assessing for pudendal nerve dysfunction in 
female patients who received SNM for refractory OAB or NOUR showed nonsignifi-
cant improvement in sexual dysfunction indices, and the authors found that these 
improvements as well as others in quality of life measures were in part due to improve-
ments in urinary function; this finding was supported by a recent review [115, 119].
3.4.3 Neuromodulation in children and adolescents
Scarce data, changing anatomy and somatic growth, physical activity, high 
reoperation rates, and neurologic instability and disease progression: all are valid 
arguments against application of SNM in children and adolescents. However, data 
is emerging on its off-label use, with modest responses. In a single center experi-
ence on eight children and adolescents with congenital lumbosacral and traumatic 
spinal cord defects and lower urinary tract dysfunction, the initial response rate 
to SNM application was 85%. This translated into a sustained efficacy in 50% of 
patients on 14-month follow-up, and three patients were able to abandon self-cath-
eterization completely. These results, although on a heterogenous and small cohort 
of young patients, are promising and could defy the current status quo [120, 121].
Nevertheless, based on lack of evidence and limited studies, the ICS best practice 
statement stressed that the safety of SNM in this population cannot be established, 
highlighting the technical challenges associated with anatomical variations and 
difference in children and effects of somatic growth [4].
4. Future directions and research
4.1 Further evaluation of effects of neuromodulation in urology
Basic science research is still ongoing and perhaps still early in deciphering 
the exact mechanism of action of neuromodulation in restoring and normalizing 
bladder function. The different levels of speculated effect, in higher brain and 
spinal centers and in the more distal micturition pathways and reflex arcs make 
for a vast field of investigation, as well as the interplay of different neural and 
cellular messengers.
A better and clearer understanding of all factors involved would definitely 
allow for the optimization of patient outcomes, including most suitable candidates, 
duration of symptoms, and required concomitant medication, if any, that would 
maximize the benefit from different neuromodulation modalities. This is of par-
ticular importance when conflicting data on different effects on receptor pathways 
and modulated areas in the brain continue to emerge, and the definition and 
descriptions of the mechanisms of action are updated.
4.2 Rechargeable and MRI-compatible systems
SNM, like any battery system, faces depletion. Thus, a rechargeable system is 
one of special appeal. Perhaps one of the most appealing arguments for upcoming 
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rechargeable systems is the fact it may potentially eliminate replacement surgery. The 
Relax-OAB study investigated the Axonics r-SNM system, a rechargeable SNM system 
granted post-marketing permission in Europe in 2016 and is under FDA assessment. 
Designed to last 15 years with charging requirements for 2 hours every 1–3 weeks, 
it has shown comparable objective improvements of up to 91% [83, 122, 123]. The 
Axonics system and the next generation InterStim Micro could revolutionize sacral 
neuromodulation durability.
The growing need for MR-compatible systems is not a wishful thought, but in 
the face of evolving biomechanical technology and a growing population that needs 
both SNM and regular MRI assessment, it seems sensible that the development of 
such devices is just a matter of time [14].
4.3 Closed-loop neuromodulation
Casually described as a system that “listens to the patient” closed-loop or 
functional stimulation is a mode of conditional electrical stimulation that is being 
investigated as a potential neuro-prosthesis that senses bladder fullness, detects 
bladder contractions, and eventually modulates an electrical response “blindly” 
without the patient having to actively control their micturition habits. To date there 
are a number of animal and limited human trials on a set of intelligent electrodes 
specifically designed to fulfill this purpose. The advantages of such a system are 
numerous, mainly bypassing chronic stimulation and subsequent bladder muscle 
fatigue through improvements in warning time for impending bladder contractions, 
as well as a more natural control on voiding and improved SNM battery life [83]. 
Many investigators have also looked into improved neurological and bladder pres-
sure sensors as a modality for functional stimulation.
4.4 Expanding indications and revisiting limited applications
Thirty years into its first reintroduction, it is still surprising how limited the 
indications for SNM in particular remain in the face of accumulating evidence, 
albeit from small trials restricted by a small pool of patients and candidates. 
Off-label use of SNM in chronic pelvic pain syndromes, pregnant women, children 
and neurogenic bladder patients should be the priority of authoritarian bodies to 
promote research and insight especially when treatment of such conditions could 
have remarkable effects on the quality of life of those affected [124].
4.5 Dorsal genital nerve stimulation
Though an existing technology, this direct PNS variation has further potential to 
modulate the combined sacral nerve roots that the former effects without the need 
of a sacral lead. Utilizing a percutaneous prepubic electrode placed on the clitoris 
to temporarily deliver electric stimulation and subsequently modulate the dorsal 
genital nerve, the anterior terminal branch of the pudendal nerve, this technology 
has been tested in small scale trials with promising results.
Hypothesized to exert its effect through inhibition of bladder efferents, 
particularly parasympathetic pathways via vesical ganglia and detrusor smooth 
muscle, the dorsal genital nerve is stimulated using an external pulse generator, 
and has been shown to reduce urgency incontinence episodes in a number of 
patient cohorts. However, the device is still not appealing due to lead migration 
and difficult controls, improvements on which would surely stir further interest 
among physicians and patients alike [82].
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5. Conclusion
Urological applications of neuromodulation are both established and evolving 
and are among the most dynamic fields for this modality of electrical stimula-
tion. The safety and efficacy of sacral neuromodulation and posterior tibial nerve 
stimulation in refractory overactive bladder syndrome are high. Other indications 
of sacral neuromodulation include non-obstructive urinary retention includ-
ing Fowler’s syndrome and urgency incontinence as well as frequency-urgency 
syndromes. Minimally invasive and broader neuromodulation targets provide 
an opportunity for improving neuromodulation outcomes, as well as potential 
advances in the device itself.
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